Tecentriq Approved to Help Young Patients Battle Metastatic Alveolar Soft Part Sarcoma (ASPS)

TUESDAY, Jan. 3, 2023 -- The U.S. Food and Drug Administration has approved the immunotherapy drug Tecentriq (atezolizumab) for use in patients with unresectable or metastatic alveolar soft part sarcoma (ASPS). The approval was granted following the...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news